Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MANNKIND CORPMNKD · Entity 4792 | EVP Genl Counsel & Secretary | July 15, 2026 | July 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MANNKIND CORP
Report date July 15, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 920,089 |
Reported balance
After 2026-07-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-15 · Exercise / conversion · Acquired 93,790 · Balance 920,089 F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 868,457 |
Reported balance
After 2026-07-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-15 · Tax withholding · Disposed 51,632 · Balance 868,457 F2: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 855,795 |
Reported balance
After 2026-07-15 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-07-15 · Tax withholding · Disposed 12,662 · Balance 855,795 F2: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 838,041 |
Reported balance
After 2026-07-15 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-07-15 · Tax withholding · Disposed 17,754 · Balance 838,041 F2: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 821,663 |
Reported balance
After 2026-07-15 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-07-15 · Tax withholding · Disposed 16,378 · Balance 821,663 F2: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. |
| Common Stock, $0.01 Par ValueSEC Table I · non-derivative | Direct | 797,554 |
Reported balance
After 2026-07-17 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2026-07-17 · Sale · Disposed 24,109 · Balance 797,554 F4: The weighted average sales price of the reported transaction was $4.05 based on a range of prices between $3.98 and $4.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3: Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025. |
| Performance Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-15 · Exercise / conversion · Disposed 93,790 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. |
Filing footnotes · ownership attribution and instrument terms
F1: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.
F2: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
F3: Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.
F4: The weighted average sales price of the reported transaction was $4.05 based on a range of prices between $3.98 and $4.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F5: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 17, 2026 Filed Jul 18, 2026 01:43 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 24,109 | $4.05 | $97,641.45 |
DisclosureSEC source: 0001193125-26-308131 · ownership.xml · nonDerivative · entry 6 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 797,554 F4 · price: The weighted average sales price of the reported transaction was $4.05 based on a range of prices between $3.98 and $4.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. F3 · acquired: Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:43 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionPerformance Restricted Stock Unit · Derivative | 93,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-308131 · ownership.xml · derivative · entry 7 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.01 Par Value · 93,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F1 · kind: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. F1 · derivative.exercise_date: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. F1 · derivative.expiration_date: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. F1 · balance_after: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:43 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 16,378 | $4.09 | $66,986.02 |
DisclosureSEC source: 0001193125-26-308131 · ownership.xml · nonDerivative · entry 5 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 821,663 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:43 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 17,754 | $4.09 | $72,613.86 |
DisclosureSEC source: 0001193125-26-308131 · ownership.xml · nonDerivative · entry 4 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 838,041 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:43 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 12,662 | $4.09 | $51,787.58 |
DisclosureSEC source: 0001193125-26-308131 · ownership.xml · nonDerivative · entry 3 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 855,795 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:43 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 51,632 | $4.09 | $211,174.88 |
DisclosureSEC source: 0001193125-26-308131 · ownership.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 868,457 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| July 15, 2026 Filed Jul 18, 2026 01:43 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionCommon Stock, $0.01 Par Value | 93,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-308131 · ownership.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 920,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. F1 · balance_after: A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria. Read SEC document |
| May 12, 2026 Filed May 14, 2026 00:30 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 3,033 | $3.29 | $9,978.57 |
DisclosureSEC source: 0001193125-26-222310 · ownership.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 826,299 F2 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established August 27, 2025. F3 · price: The weighted average sales price of the reported transaction was $3.29 based on a range of prices between $3.25 and $3.34. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 11, 2026 Filed May 14, 2026 00:30 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 12,387 | $3.52 | $43,602.24 |
DisclosureSEC source: 0001193125-26-222310 · ownership.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 829,332 F1 · shares: Represents shares withheld to pay tax withholding obligations due on the date of vesting of the Restricted Stock Units originally granted on May 10, 2022. Read SEC document |
| March 23, 2026 Filed Mar 26, 2026 01:30 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 217,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0001193125-26-124721 · ownership.xml · derivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,000 Underlying: Common Stock, $0.01 Par Value · 217,000 shares Expires 2036-03-23 F3 · derivative.exercise_date: 25% vesting on March 23, 2027 and thereafter 1/16th quarterly. Read SEC document |
| March 23, 2026 Filed Mar 26, 2026 01:30 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 221,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-124721 · ownership.xml · derivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,000 Underlying: Common Stock, $0.01 Par Value · 221,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F2 · derivative.expiration_date: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 02:50 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 37,525 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001193125-26-086377 · ownership.xml · derivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,525 Underlying: Stock Options · 37,525 shares Expires 2027-05-25 F2 · kind: On May 25, 2017, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On February 26, 2026, one of the defined performance milestones was met, resulting in the partial vesting of the option. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 02:50 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001193125-26-086377 · ownership.xml · derivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Stock Options · 20,000 shares Expires 2026-05-19 F1 · kind: On May 19, 2016, the reporting person was granted an option that vests upon the achievement of certain defined performance milestones. On February 26, 2026, one of the defined performance milestones was met, resulting in the partial vesting of the option. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:27 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 87,780 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001193125-25-308347 · ownership.xml · derivative · entry 7 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.01 Par Value · 87,780 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:27 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001193125-25-308347 · ownership.xml · derivative · entry 6 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.01 Par Value · 20,000 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:27 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001193125-25-308347 · ownership.xml · derivative · entry 5 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.01 Par Value · 20,000 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:27 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001193125-25-308347 · ownership.xml · derivative · entry 4 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.01 Par Value · 20,000 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:27 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 147,780 | $5.57 | $823,134.60 |
DisclosureSEC source: 0001193125-25-308347 · ownership.xml · nonDerivative · entry 3 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 841,719 F1 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established August 27, 2025. F2 · price: The weighted average sales price of the reported transaction was $5.57 based on a range of prices between $5.50 and $5.63. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:27 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionCommon Stock, $0.01 Par Value | 87,780 | $4.60 | $403,788.00 |
DisclosureSEC source: 0001193125-25-308347 · ownership.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 989,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:27 UTC | MANNKIND CORP MNKD · Entity 4792 | Exercise / conversionCommon Stock, $0.01 Par Value | 60,000 | $4.55 | $273,000.00 |
DisclosureSEC source: 0001193125-25-308347 · ownership.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 901,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 00:46 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 7,466 | $3.94 | $29,416.04 |
DisclosureSEC source: 0000950170-25-096737 · ownership.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 841,719 F2 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established August 19, 2024. F3 · price: The weighted average sales price of the reported transaction was $3.94 based on a range of prices between $3.90 and $3.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| July 15, 2025 Filed Jul 18, 2025 00:46 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 30,361 | $3.85 | $116,889.85 |
DisclosureSEC source: 0000950170-25-096737 · ownership.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 849,185 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 20, 2025 Filed May 21, 2025 01:44 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 2,345 | $4.41 | $10,341.45 |
DisclosureSEC source: 0000950170-25-075534 · ownership.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 879,546 F2 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established August 19, 2024. F3 · price: The weighted average sales price of the reported transaction was $4.41 based on a range of prices between $4.38 and $4.46. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 19, 2025 Filed May 21, 2025 01:44 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 9,536 | $4.37 | $41,672.32 |
DisclosureSEC source: 0000950170-25-075534 · ownership.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 881,891 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 13, 2025 Filed May 16, 2025 01:37 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 145,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073082 · ownership.xml · derivative · entry 6 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock, $0.01 Par Value · 145,000 shares Expires not disclosed F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F7 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F7 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 13, 2025 Filed May 16, 2025 01:37 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 119,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073082 · ownership.xml · nonDerivative · entry 5 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 891,427 F5 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on July 15, 2026 and each yearly anniversary thereof until fully vested. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. Read SEC document |
| May 13, 2025 Filed May 16, 2025 01:37 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 32,179 | $4.68 | $150,597.72 |
DisclosureSEC source: 0000950170-25-073082 · ownership.xml · nonDerivative · entry 4 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 772,427 F3 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established August 19, 2024. F4 · price: The weighted average sales price of the reported transaction was $4.68 based on a range of prices between $4.65 and $4.81. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 12, 2025 Filed May 16, 2025 01:37 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 12,364 | $4.56 | $56,379.84 |
DisclosureSEC source: 0000950170-25-073082 · ownership.xml · nonDerivative · entry 3 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 804,606 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 12, 2025 Filed May 16, 2025 01:37 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 118,473 | $4.56 | $540,236.88 |
DisclosureSEC source: 0000950170-25-073082 · ownership.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 816,970 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 10, 2025 Filed May 16, 2025 01:37 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 105,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073082 · ownership.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 935,443 F1 · kind: A previously reported restricted stock unit award granted on May 10, 2022 vested on May 10, 2025 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 9, 2025 was not less than the closing price on May 10, 2022 and (ii) MannKind's total shareholder return (TSR) over the period from May 10, 2022 to May 10, 2025 was at the 73.9th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 196% of target, resulting in a total share delivery of 215,600 shares. The acquisition of 110,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on May 12, 2022. Read SEC document |
| August 29, 2024 Filed Aug 30, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 5,553 | $5.94 | $32,984.82 |
DisclosureSEC source: 0000950170-24-102040 · ownership.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 829,843 F2 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established September 5, 2023. Read SEC document |
| August 27, 2024 Filed Aug 30, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 22,489 | $5.38 | $120,990.82 |
DisclosureSEC source: 0000950170-24-102040 · ownership.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 835,396 F1 · kind: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of previously reported restricted stock units. Read SEC document |
| July 16, 2024 Filed Jul 17, 2024 23:49 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 3,115 | $5.93 | $18,471.95 |
DisclosureSEC source: 0000950170-24-084403 · ownership.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 857,885 F2 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established September 5, 2023. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 23:49 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 12,616 | $5.83 | $73,551.28 |
DisclosureSEC source: 0000950170-24-084403 · ownership.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 861,000 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 21, 2024 Filed May 22, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $0.01 Par Value | 23,537 | $4.66 | $109,682.42 |
DisclosureSEC source: 0000950170-24-063262 · ownership.xml · nonDerivative · entry 4 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 873,616 F3 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established September 5, 2023. Read SEC document |
| May 18, 2024 Filed May 22, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 6,916 | $4.59 | $31,744.44 |
DisclosureSEC source: 0000950170-24-063262 · ownership.xml · nonDerivative · entry 3 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 897,153 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 17, 2024 Filed May 22, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $0.01 Par Value | 85,797 | $4.59 | $393,808.23 |
DisclosureSEC source: 0000950170-24-063262 · ownership.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 904,069 F2 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 17, 2024 Filed May 22, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $0.01 Par Value | 77,420 | $4.59 | $355,357.80 |
DisclosureSEC source: 0000950170-24-063262 · ownership.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 989,866 F1 · kind: A previously reported restricted stock unit award granted on May 18, 2021 vested on May 17, 2024 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 17, 2024 was not less than the closing price on May 17, 2021 and (ii) MannKind's total shareholder return (TSR) over the period from May 18, 2021 to May 17, 2024 was at the 74.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 198% of target, resulting in a total share delivery of 156,420 shares. The acquisition of 79,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on May 18, 2021. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 158,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062069 · ownership.xml · derivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,000 Underlying: Common Stock, $.01 Par Value · 158,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 15, 2024 Filed May 18, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $.01 Par Value | 129,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062069 · ownership.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 912,446 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · kind: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 13, 2024 Filed May 15, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 3,047 | $4.31 | $13,132.57 |
DisclosureSEC source: 0000950170-24-059962 · ownership.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 783,446 F2 · kind: Transaction occurred pursuant to Rule 10b5-1 Plan established September 5, 2023. Read SEC document |
| May 10, 2024 Filed May 15, 2024 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 12,342 | $4.32 | $53,317.44 |
DisclosureSEC source: 0000950170-24-059962 · ownership.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 786,493 F1 · kind: Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units. Read SEC document |
| August 28, 2023 Filed Aug 29, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 8,100 | $4.78 | $38,738.25 |
DisclosureSEC source: 0001209191-23-047550 · doc4.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 798,835 F2 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan established November 17, 2022. Read SEC document |
| August 27, 2023 Filed Aug 29, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 20,328 | $4.72 | $95,948.16 |
DisclosureSEC source: 0001209191-23-047550 · doc4.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 806,935 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:01 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantPerformance Restricted Stock Unit · Derivative | 113,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032728 · doc4.xml · derivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,000 Underlying: Common Stock, $.01 Par Value · 113,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.underlying_shares: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:01 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $.01 Par Value | 92,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032728 · doc4.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 827,263 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 24, 2023 Filed May 25, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | SaleCommon Stock, $.01 Par Value | 95,576 | $4.68 | $447,754.44 |
DisclosureSEC source: 0001209191-23-032035 · doc4.xml · nonDerivative · entry 3 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 735,263 F3 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan. Read SEC document |
| May 22, 2023 Filed May 25, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 281,414 | $4.79 | $1,347,973.06 |
DisclosureSEC source: 0001209191-23-032035 · doc4.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 830,839 F2 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 22, 2023 Filed May 25, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | GrantCommon Stock, $.01 Par Value | 400,000 | $4.79 | $1,916,000.00 |
DisclosureSEC source: 0001209191-23-032035 · doc4.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,112,253 F1 · kind: A previously reported restricted stock unit award granted on August 27, 2020 vested on May 22, 2023 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 22, 2023 was not less than the closing price on August 27, 2020 and (ii) the percentile ranking of MannKind's total shareholder return (TSR) over the period from August 27, 2020 to May 22, 2023 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period was greater than the 90th percentile. As a result, the performance objective was achieved at 300% of target, resulting in a total share delivery of 600,000 shares. The acquisition of 200,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on August 31, 2020. Read SEC document |
| May 18, 2023 Filed May 20, 2023 01:00 UTC | MANNKIND CORP MNKD · Entity 4792 | Tax withholdingCommon Stock, $.01 Par Value | 6,001 | $4.56 | $27,364.56 |
DisclosureSEC source: 0001209191-23-031288 · doc4.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 712,253 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.